# Visioneering Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/visioneering-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Alpharetta, US
- Website: www.vtivision.com
- Total disclosed funding: $5M
- Latest round: Series B (Apr 14, 2009)
- Investors on record: 4

## About

Visioneering Technologies, Inc. is a specialized company focused on developing and manufacturing innovative contact lens solutions to enhance vision correction and comfort for users.Founded in 2008 and headquartered in Alpharetta, US, Visioneering Technologies, Inc. develops advanced contact lenses. The company has engaged in four deals, with its latest funding round being an IPO on March 17, 2017, raising AUD 33.3 million. Richard Griffin founded the company, and it is now led by CEO Juan Aragón and Stephen Snowdy.Visioneering Technologies, Inc. specializes in the development and manufacturing of NaturalVue® Brand contact lenses, specifically designed for daily wear. Their core products include the NaturalVue® Enhanced Sphere 1 Day Contact Lenses and the NaturalVue® Enhanced Multifocal 1 Day Disposable Soft Contact Lenses, which utilize a TripleTear™ lubrication system to enhance wearer comfort. These contact lenses aim to address refractive ametropia, including myopia and hyperopia, as well as presbyopia, catering to individuals with normal eyesight and astigmatism of up to 2.00 diopters. The company's products are marketed to eye care practitioners and are available in several geographical regions, including North America, Europe, the Middle East, and parts of Asia Pacific, ensuring a broad client base of both healthcare professionals and end consumers seeking effective vision correction solutions.Visioneering Technologies, Inc. generated revenue of AUD 5,105,000 in the most recent year, 2020, with an EBITDA of AUD -7,542,000. Their revenue primarily comes from the direct sale of NaturalVue® contact lenses to eye care practitioners and retailers, facilitating access to their products for a wider array of patients. The pricing structure supports both individual practitioners and larger retail entities, fostering partnerships that enhance product distribution and accessibility.Following their IPO on March 17, 2017, where they raised AUD 33.3 million, Visioneering Technologies intends to focus on the development of new products in the NaturalVue® line, with specific plans for expansion into new markets in Europe and Asia by 2025. The recent funding will support these initiatives by enhancing research and development capabilities and increasing market penetration.

## Funding rounds

- Series B, Apr 14, 2009, $5M — Charter Life Sciences, MB Venture Partners, Life Science Angels, Inc., Georgia Tech ATDC VentureLab

## Investors

- Charter Life Sciences (https://capitalatlas.ai/funds/charter-life-sciences) — Series B
- MB Venture Partners (https://capitalatlas.ai/funds/mb-venture-partners) — Series B
- Life Science Angels, Inc. — Series B
- Georgia Tech ATDC VentureLab — Series B